Fallopian Tube Cancer Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Conditions: Gynecologic Cancer; Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cavity Cancer Interventions: Drug: FT536; Drug: Fludarabine; Drug: CY Sponsors: Masonic Cancer Center, University of Minnesota Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials

NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Conditions: Ovarian Carcinoma; Fallopian Tube Carcinoma; Peritoneal Carcinoma; Endometrial Cancer; Adenocarcinoma of Lung; Triple Negative Breast Cancer; Liposarcoma; Leiomyosarcoma; Mesothelioma, Malignant; Adenocarcinoma - Gastroesophageal Junction (GEJ); Adenocarcinoma of the Stomach; Melanoma, Malignant; Renal Cell Carcinoma Interventions: Biological: NM32-2668 Sponsors: Numab Therapeutics AG Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 7, 2024 Category: Research Source Type: clinical trials

Clonal Hematopoiesis in Ovarian Cancer Survivors and Risk of Secondary Blood Cancers
Conditions: Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma Interventions: Other: Non-Interventional Study Sponsors: University of Washington; National Cancer Institute (NCI) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2024 Category: Research Source Type: clinical trials

Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Primary Cytoreductive Surgery
Conditions: Ovarian Cancer; Fallopian Tube Carcinoma; Ovarian Carcinoma; Peritoneal Carcinoma; Ovarian Cancer Stage IIIC; Fallopian Tube Cancer Stage IIIC; Ovarian Cancer Stage IV; Fallopian Tube Cancer Stage IV; Fallopian Tube Cancer; Peritoneal Cancer Interventions: Biological: Acute Normovolemic Hemodilution/ANH Sponsors: Memorial Sloan Kettering Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials

Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study
Conditions: Serous Ovarian Tumor; Endometrioid Carcinoma Ovary; Fallopian Tube Cancer; Primary Peritoneal Carcinoma Interventions: Genetic: Somatic and Germline BRCA1/2 Testing Sponsors: Cancer Trials Ireland Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2024 Category: Research Source Type: clinical trials

SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery
Conditions: Epithelial Ovarian Cancer; Fallopian Tube Neoplasms; Peritoneal Neoplasms Interventions: Procedure: Cytoreductive surgery; Drug: Neoadjuvant chemotherapy; Drug: Adjuvant chemotherapy Sponsors: Clinica Universidad de Navarra, Universidad de Navarra; Asociaci ón de Amigos de la Universidad de Navarra Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 25, 2024 Category: Research Source Type: clinical trials

Choices About Genetic Testing And Learning Your Risk With Smart Technology
Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Breast Cancer; Pancreas Cancer; Colorectal Cancer; Endometrial Cancer; Prostate Cancer Interventions: Device: Relational Agent; Other: Clinical Letter Sponsors: Rutgers, The State University of New Jersey Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 28, 2023 Category: Research Source Type: clinical trials

RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Conditions: Primary Peritoneal Cancer; Fallopian Tube; Epithelial Ovarian Interventions: Drug: RC88 Sponsors: RemeGen Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 15, 2023 Category: Research Source Type: clinical trials

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi
Conditions: Ovarian Cancer; High Grade Serous Adenocarcinoma of Ovary; Primary Peritoneal Carcinoma; Fallopian Tube Cancer Interventions: Drug: Fluzoparib; Drug: Fluzoparib+Apatinib Sponsors: Guangxi Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 7, 2023 Category: Research Source Type: clinical trials

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Solid Cancer Interventions: Drug: R-DXd; Drug: Gemcitabine; Drug: Paclitaxel; Drug: Topotecan; Drug: PLD Sponsors: Daiichi Sankyo, Inc.; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 7, 2023 Category: Research Source Type: clinical trials

Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab
Conditions: Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Interventions: Drug: Niraparib Sponsors: Peking University Cancer Hospital& Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 21, 2023 Category: Research Source Type: clinical trials

A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer Interventions: Drug: KAND567; Drug: Carboplatin Sponsors: Kancera AB; Nordic Society of Gynaecological Oncology - Clinical Trials Unit Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 17, 2023 Category: Research Source Type: clinical trials

A Phase Ib Study of Sovilnesib in Subjects With Ovarian Cancer
Conditions: High Grade Serous Adenocarcinoma of Ovary; Fallopian Tube Cancer; Primary Peritoneal Carcinoma; Chromosomal Instability Interventions: Drug: Sovilnesib Sponsors: Volastra Therapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials

A Study of Sovilnesib in Subjects With Ovarian Cancer
Conditions: High Grade Serous Adenocarcinoma of Ovary; Fallopian Tube Cancer; Primary Peritoneal Carcinoma; Chromosomal Instability Interventions: Drug: Sovilnesib Sponsors: Volastra Therapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer
Conditions: Ovarian Cancer; High Grade Serous Adenocarcinoma of Ovary; High Grade Endometrioid Ovarian Cancer; Primary Peritoneal Cancer; Fallopian-tube Cancer Interventions: Drug: Fluzoparib Capsules; Drug: Bevacizumab Sponsors: Sun Yat-sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 2, 2023 Category: Research Source Type: clinical trials